K8凯发官网

專注给予質高價優

的生物藥

科學論文

A phase 2 study of HLX208, a BRAFV600E inhibitor, in adult patients with Langerhans cell histiocytosis and/or Erdheim-Chester disease harboring BRAFV600E mutation.
ASCO 2023
Safety, Preliminary Efficacy, and Pharmacokinetics of HLX26 plus Serplulimab in Advanced Solid Tumours: an Open-label, Dose-escalation Phase 1 Study
ESMO Asia 2023
safety, tolerability,and pharmacokinetics of HLX26(an anti-LAG3 antibody) in patients with advanced or metastatic solid tumors or lymphomas.
ASCO 2023
A phase 2 study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma
ESMO Asia 2023
Phase 3 study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small-cell lung cancer: ASTRUM-004 Asian subgroup
ESMO Asia 2023
A Phase 3 study of Serplulimab Plus Chemotherapy as First - Line Treatment for Squamous Non-small-cell Lung Cancer (ASTRUM-004）
WCLC 2023

知識產權

專利申請數量	PCT申請數量	國內外授權專利數量	註冊司法權區	申請日期	到期日	發明專利數量
809	90	134	中國大陸	2011-03-18	2031-03-18	97